The latest update is out from JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ).
JW (Cayman) Therapeutics Co. Ltd. has entered into a Material Transfer Agreement with Juno, a substantial shareholder and connected person, to receive vials of Vector valued at over US$1 million. This transaction is classified as a connected transaction under the Hong Kong Listing Rules and is subject to reporting and announcement requirements. The agreement allows Juno to use Preliminary sLVV Information for transition planning, with certain contingencies in place regarding the execution of the sLVV License Agreement.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a company incorporated in the Cayman Islands, operating in the biotechnology sector. The company focuses on developing and delivering innovative cell-based therapies for cancer treatment.
YTD Price Performance: 66.41%
Average Trading Volume: 1,437,011
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$885.3M
See more insights into 2126 stock on TipRanks’ Stock Analysis page.